Comparative Pharmacology
Head-to-head clinical analysis: LUCEMYRA versus LUMIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCEMYRA versus LUMIFY.
LUCEMYRA vs LUMIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
Selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
Instill 1 drop in the affected eye(s) every 6 to 8 hours as needed, not to exceed 4 drops per eye per day.
None Documented
None Documented
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Approximately 2.5-3 hours (terminal) in adults; clinical context: duration of mydriasis may be shorter than half-life due to receptor binding.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Primarily renal (60-70% unchanged), with biliary/fecal elimination accounting for the remainder.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist